Filana Therapeutics (FLNA) EBIT (2010 - 2026)

Filana Therapeutics has reported EBIT for 17 years, with the latest figure at -$9.4 million in Q2 2026.

• On a quarterly basis, EBIT rose 79.31% year-over-year to -$9.4 million in Q2 2026; TTM through Jun 2026 was -$46.0 million, a 64.66% increase from a year earlier, with the FY2025 full-year figure at -$95.4 million, up 32.56% from the prior year.
• EBIT was -$9.4 million for Q2 2026 at Filana Therapeutics, up from -$11.2 million in the prior quarter.
• The five-year high for EBIT was -$9.4 million in Q2 2026, with the low at -$61.4 million in Q2 2024.
• Average EBIT over 5 years is -$24.6 million, with a median of -$22.1 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: EBIT plunged 404.42% in 2022, then jumped 79.31% in 2026.
• Over 5 years, EBIT stood at -$20.9 million in 2022, then declined by 8.85% to -$22.8 million in 2023, then declined by 29.39% to -$29.5 million in 2024, then jumped by 54.04% to -$13.6 million in 2025, then jumped by 30.69% to -$9.4 million in 2026.
• The last three EBIT figures came in at -$9.4 million (Q2 2026), -$11.2 million (Q1 2026), and -$13.6 million (Q4 2025), per Business Quant data.